Literature DB >> 28482576

Folate-decorated PEGylated triblock copolymer as a pH/reduction dual-responsive nanovehicle for targeted intracellular co-delivery of doxorubicin and Bcl-2 siRNA.

Aili Suo1, Junmin Qian2, Minghui Xu3, Weijun Xu3, Yaping Zhang3, Yu Yao4.   

Abstract

Co-delivery of chemotherapeutic drug and small interfering RNA (siRNA) within a single nanovehicle has emerged as a promising combination therapy approach to treating cancers because of their synergistic effect. Nanocarrier delivery systems with low cytotoxicity and high efficiency are needed for such a purpose. In this study, a novel folate-conjugated PEGylated cationic triblock copolymer, poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine) (PAH-b-PDMAPMA-b-PAH), was synthesized and evaluated as a stimuli-sensitive vehicle for the targeted co-delivery of doxorubicin (DOX) and Bcl-2 siRNA into breast cancer MCF-7 cells. The synthetic process of the PEGylated triblock copolymer involved sequential reversible addition-fragmentation chain transfer polymerization, PEGylation and removal of tert-butoxy carbamate protecting groups. Folate-conjugated and/or -unconjugated poly(ethylene glycol) segments were grafted onto PAH-b-PDMAPMA-b-PAH via a reduction-sensitive disulfide linkage. The synthetic polymers were characterized by 1H NMR and gel permeation chromatography. The PEGylated triblock copolymer could chemically conjugate DOX onto PAH blocks via pH-responsive hydrazone bonds and simultaneously complex negatively charged Bcl-2 siRNA with cationic PDMAPMA blocks through electrostatic interactions at N/P ratios≥32:1 to form multifunctional nanomicelleplexes. The nanomicelleplexes exhibited spherical shape, possessed a positively charged surface with a zeta potential of +22.5mV and had a desirable and uniform particle size of 187nm. In vitro release studies revealed that the nanomicelleplexes could release DOX and Bcl-2 siRNA in a reduction and pH dual-sensitive manner and the payload release was significantly enhanced in a reductive acidic environment mimicking the endosomes/lysosomes of cancer cells compared to under physiology conditions. Furthermore, the release of both DOX and siRNA was found to follow Higuchi kinetic model. Confocal laser scanning microscopy, flow cytometry and MTT analyses confirmed that, compared with folate-undecorated nanomicelleplexes, folate-decorated nanomicelleplexes could more effectively co-deliver DOX and Bcl-2 siRNA into MCF-7 cells and showed a stronger cell-killing effect. The pristine PEGylated triblock copolymer exhibited good cytocompatibility. Moreover, co-delivery of DOX and Bcl-2 siRNA achieved a significant synergistic antitumor efficacy. These findings suggested that the folate-decorated PEGylated cationic triblock copolymer might be a promising vehicle for targeted intracellular co-delivery of DOX and siRNA in MCF-7 cells, representing a potential clinical combination therapy for breast cancer treatment.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bcl-2 siRNA; Breast cancer; Combination therapy; Doxorubicin; RAFT polymerization; Targeted delivery

Mesh:

Substances:

Year:  2017        PMID: 28482576     DOI: 10.1016/j.msec.2017.03.124

Source DB:  PubMed          Journal:  Mater Sci Eng C Mater Biol Appl        ISSN: 0928-4931            Impact factor:   7.328


  7 in total

1.  Co-delivery of curcumin and Bcl-2 siRNA by PAMAM dendrimers for enhancement of the therapeutic efficacy in HeLa cancer cells.

Authors:  Maryam Ghaffari; Gholamreza Dehghan; Behzad Baradaran; Amir Zarebkohan; Behzad Mansoori; Jafar Soleymani; Jafar Ezzati Nazhad Dolatabadi; Michael R Hamblin
Journal:  Colloids Surf B Biointerfaces       Date:  2019-12-27       Impact factor: 5.268

2.  Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro.

Authors:  Rui-Min Long; Qing-Lei Dai; Xia Zhou; Duan-Hua Cai; Ya-Zhen Hong; Shi-Bin Wang; Yuan-Gang Liu
Journal:  Int J Nanomedicine       Date:  2018-12-04

3.  Redox/pH-Responsive 2-in-1 Chimeric Nanoparticles for the Co-Delivery of Doxorubicin and siRNA.

Authors:  Hsi-Chin Wu; Wei-Ting Kuo
Journal:  Polymers (Basel)       Date:  2021-12-13       Impact factor: 4.329

4.  Chemosensitizing effect and mechanism of imperatorin on the anti-tumor activity of doxorubicin in tumor cells and transplantation tumor model.

Authors:  Xin-Li Liang; Miao-Miao Ji; Zheng-Gen Liao; Guo-Wei Zhao; Xi-Lan Tang; Wei Dong
Journal:  Korean J Physiol Pharmacol       Date:  2022-05-01       Impact factor: 2.016

Review 5.  Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology.

Authors:  Jinxing Huang; Kai Xiao
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

6.  Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal.

Authors:  Sahar Eljack; Stephanie David; Areeg Faggad; Igor Chourpa; Emilie Allard-Vannier
Journal:  Int J Pharm X       Date:  2022-09-06

7.  Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy.

Authors:  Milad Ashrafizadeh; Ali Zarrabi; Kiavash Hushmandi; Farid Hashemi; Ebrahim Rahmani Moghadam; Mehdi Raei; Mahshad Kalantari; Shima Tavakol; Reza Mohammadinejad; Masoud Najafi; Franklin R Tay; Pooyan Makvandi
Journal:  ACS Comb Sci       Date:  2020-10-23       Impact factor: 3.784

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.